Selective binding of oxalate by a tris-ureido calix[6]tube in a protic environment.

Due to their significant role in industry and biological systems, the interest in selectively recognizing and detecting small dicarboxylates has grown in recent years. In this study, we report on the binding properties of a family of tubular-shaped heterotritopic receptors based on bis-calix[6]arenes, which contain three (thio)urea bridges (C3U and C3TU) or six urea bridges (C6U), toward dicarboxylates. While poor binding properties were observed by NMR for the newly synthesized C6U, receptors C3U and C3TU exhibited a unique ability to cooperatively complex a dicarboxylate anion sandwiched between two ammonium ions. The three ions are complexed in contact and aligned within the tubular shape of the receptor, forming cascade complexes that are stable even in a competitive environment. The different binding properties between the receptors were rationalized in terms of size, flexibility, H-bond donor ability, and intramolecular H-bonding within the anion binding pocket between the calixarene cavities. With C3U, a rare selectivity for oxalate over other small dicarboxylates and various bicharged anions was observed. Molecular modeling of the cascade complex indicated that the oxalate anion is stabilized by an array of hydrogen bonds with the urea bridges of the receptor and both propylammonium cations nested within the calixarene cavities.

3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.

Bicyclic chiral scaffolds are privileged motifs in medicinal chemistry. Over the years, we have reported covalent bicyclic prolyl oligopeptidase inhibitors that were highly selective for POP over a number of homologous proteins. Herein, we wish to report the structure-based design and synthesis of a novel class of POP inhibitors based on hexahydroisoindoles. A docking study guided the selection of structures for synthesis. The stereochemistry, decoration, and position within the molecule of the bicyclic scaffolds were assessed virtually. Following the synthesis of the best candidates, in vitro assays revealed that one member of this chemical series was more active than any of our previous inhibitors with a Ki of 1.0 nM. Additional assays also showed that the scaffold of this potent inhibitor, in contrast to one of our previously reported chemical series, is highly metabolically stable, despite the foreseen potential sites of metabolism. Interestingly, computer docking calculations accurately predicted the optimal features of the inhibitors.

Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.

In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons et al., we concentrate our attention on an updated list of compounds under clinical evaluation (phase I/II/III) and discuss their mode of action as ATP-competitive inhibitors. CDK inhibition profiles and clinical development stages are reported for the 14 compounds under clinical evaluation. Also, tentative progress for forthcoming potential ATP non-competitive inhibitors and allosteric inhibitors are briefly described, along with their limitations.

Silver-catalyzed domino hydroarylation/cycloisomerization reactions of ortho-alkynylbenzaldehydes: an entry to functionalized isochromene derivatives.

A Ag-catalyzed versatile and efficient access to 1H,1-arylisochromenes is reported. Starting from ortho-alkynylbenzaldehydes bearing various substitution patterns on the benzaldehyde and alkynyl units, the use of silver triflate (10 mol %) allowed a domino hydroarylation/cycloisomerization reaction process, leading to aryl-functionalized 1H-isochromene (>10 compounds, 80-98% yields). Notably, the reaction conditions were also compatible with benzaldehydes bearing an aliphatic-substituted alkynyl moiety with modest to good yields (34-88%, 10 compounds).